Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rochelle Bagatell

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Current Opinion in Pediatrics|November 28, 2018
Advances in neuroblastoma therapySuzanne MacFarland, Rochelle Bagatell
Molecular Cancer Therapeutics|August 10, 2004
Altered Hsp90 function in cancer: a unique therapeutic opportunityRochelle Bagatell, Luke Whitesell
Current Opinion in Pediatrics|November 18, 2015
Genetic discoveries and treatment advances in neuroblastomaRochelle Bagatell, Susan L Cohn
Nature Reviews. Clinical Oncology|October 22, 2014
Mechanisms of neuroblastoma regressionGarrett M Brodeur, Rochelle Bagatell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?David M Barrett, Rochelle Bagatell
JAMA|August 28, 2019
Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision MedicineRochelle Bagatell, Meredith S Irwin
The Lancet. Oncology|March 6, 2017
Refining megatherapy, improving outcome in neuroblastomaRochelle Bagatell, Stephan A Grupp
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2021
Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized TrialsSteven G DuBois, Rochelle Bagatell
Current Cancer Drug Targets|October 8, 2003
The stress response: implications for the clinical development of hsp90 inhibitorsLuke Whitesell, Rochelle Bagatell, Ryan Falsey
Pediatric Blood & Cancer|November 13, 2010
Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005Kelsey A Johnson, Richard Aplenc, Rochelle Bagatell
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Current Opinion in Pediatrics|November 28, 2018
Advances in neuroblastoma therapySuzanne MacFarland, Rochelle Bagatell
Molecular Cancer Therapeutics|August 10, 2004
Altered Hsp90 function in cancer: a unique therapeutic opportunityRochelle Bagatell, Luke Whitesell
Current Opinion in Pediatrics|November 18, 2015
Genetic discoveries and treatment advances in neuroblastomaRochelle Bagatell, Susan L Cohn
Nature Reviews. Clinical Oncology|October 22, 2014
Mechanisms of neuroblastoma regressionGarrett M Brodeur, Rochelle Bagatell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?David M Barrett, Rochelle Bagatell
JAMA|August 28, 2019
Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision MedicineRochelle Bagatell, Meredith S Irwin
The Lancet. Oncology|March 6, 2017
Refining megatherapy, improving outcome in neuroblastomaRochelle Bagatell, Stephan A Grupp
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2021
Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized TrialsSteven G DuBois, Rochelle Bagatell
Current Cancer Drug Targets|October 8, 2003
The stress response: implications for the clinical development of hsp90 inhibitorsLuke Whitesell, Rochelle Bagatell, Ryan Falsey
Pediatric Blood & Cancer|November 13, 2010
Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005Kelsey A Johnson, Richard Aplenc, Rochelle Bagatell
Pageof 15